Skip to main content
Go to the home page of the European Commission (opens in new window)
English en
CORDIS - EU research results
CORDIS

VIVA-ELISA: Advanced Laboratory Test for Rapid Detection of NLRP3 Inflammasome Activation in Critical Septic Patients

Project description

Fast-tracking sepsis diagnosis

An estimated 50 million cases of sepsis occur each year, resulting in 13.7 million deaths, nearly 20 % of all global deaths. Sepsis is difficult to diagnose, and even after diagnosis, predicting which patients will deteriorate quickly remains a challenge. This delay worsens outcomes, prolongs recovery and increases healthcare costs. Funded by the European Innovation Council, the VIVA-ELISA project addresses this with an innovative blood test that detects early dysfunction of the NLRP3 inflammasome in monocytes, a strong predictor of severe outcomes. Identifying this within the first 24 hours allows clinicians to stratify patients by immune profile, personalise treatments and guide timely decisions. VIVA-ELISA's work aims to reduce sepsis mortality by 25-40 %, accelerate recovery and ease strain on healthcare systems.

Objective

Sepsis causes almost 20% of global annual deaths. It involves a dysregulated systemic inflammatory response driven by proinflammatory cytokines. If untreated, it progresses to organ dysfunction, low blood pressure, and septic shock. Current diagnosis methods have low predictability, delays in diagnosis, lack of sensitivity, and an inability to predict the course of the patients deterioration: there is thus a need for a rapid, accurate, affordable and early identification of the mortality risk.
VIVA-ELISA is a follow-up to the ERC project SPEDI-TEST conducted at the Biomedical Research Institute of Murcia (IMIB), of which Viva in Vitro is a spin-off. Studies show that 100% of deaths of septic patients are correlated to early impairment of the NLRP3 inflammasome activation in monocytes, in the initial 24 h. A novel in vitro diagnostic method was developed for the fast detection of early impairment of the NLRP3 inflammasome activation. This method can stratify patients at a higher risk of developing life-threatening complications, resulting in an early and more accurate prognosis.
VIVA-ELISA will advance this concept by developing an easy-to-use, highly sensitive immunoassay that can be seamlessly implemented into hospitals and clinics, reducing time-to-treatment, variability in data interpretation, and hospitalization costs, currently averaging $32,000 per patient. Our solution, designed as a classic quantitative sandwich ELISA, requires only a small blood sample to measure ex vivo NLRP3 activation. We aim to reduce sepsis mortality rates by 25 to 40%, reduce morbidity and recovery time, reduce chronic sequelae for patients and enable the possibility of personalized treatments and immunotherapy, while also contributing to the sustainability of healthcare systems.
VIVA-ELISA will also validate this technology in initial clinical studies and will carry out the necessary work to comply with current EU/US regulations before its introduction into the market.

Fields of science (EuroSciVoc)

Keywords

Programme(s)

Topic(s)

Funding Scheme

HORIZON-EIC - HORIZON EIC Grants

See all projects funded under this funding scheme

Call for proposal

(opens in new window) HORIZON-EIC-2024-TRANSITION-01

See all projects funded under this call

Coordinator

VIVA IN VITRO DIAGNOSTICS SL
Net EU contribution
€ 2 493 003,89
Address
PQUE CIENTIFICO MURCIA CTRA DE MADRID KM 388 EDIF T PLANTA 1
30100 MURCIA
Spain
SME
Yes
Region
Sur Región de Murcia Murcia
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Links
Total cost
No data